Bcal Diagnostics (BDX) Short Interest
Bcal Diagnostics (ASX:BDX) had 0.00% of shares reported as short positions as of 2 June 2025, representing 304 shares. Bcal Diagnostics operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Bcal Diagnostics
BCAL Diagnostics Limited is an Australian biotechnology company focused on developing a non-invasive blood test for breast cancer detection. They aim to complement existing imaging technologies and improve screening outcomes. BCAL has a NATA-accredited commercial laboratory and has partnered with ClearNote Health Inc. to expand its diagnostic portfolio.
Short position
Bcal Diagnostics (ASX:BDX) has 0.00% of its shares on issue reported as short positions as of 2 June 2025, or about 304 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has fallen 0.12 percentage points. Its highest recorded short interest was 0.36% in July 2021. BDX is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Weekly context: The 10 most shorted ASX stocks — Week 35, 2026.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4BDX intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Bcal Diagnostics
About
website
address
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss BDX
Start a research thread or post the first pulse update